No Data
No Data
Agilent Partners With NUS to Advance Cardiovascular Research in Singapore
Agilent Is Maintained at Underweight by Barclays
(A) - Analyzing Agilent Technologies's Short Interest
Barclays Adjusts Price Target on Agilent Technologies to $145 From $135
$1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
Australia & New Zealand Research Antibodies Market Report 2024-2030, With Leading Players Abcam, BD, Merck, Lonza, Cell Signaling Technology, F. Hoffmann-La Roche, Agilent Technologies, Revvity & More
No Data
No Data
BLACKLIST00 : On stock
Credible Commerce : Nicely done I’m still working lol